ORAL CHEMO MEDICATION H.B. 4071 (S-1):

SUMMARY OF BILL

REPORTED FROM COMMITTEE

 

 

 

 

 

 

House Bill 4071 (Substitute S-1 as reported)

Sponsor: Representative Samantha Steckloff

House Committee: Health Policy

Senate Committee: Health Policy

 


CONTENT

 

The bill would add Section 3406ff to the Insurance Code to require equal financial treatment of orally administered, intravenously administered, and injected antineoplastic (anticancer) medication. It also would limit the co-pay or coinsurance for orally administered antineoplastic medication to $250 per 30-day supply.

 

The bill would apply to health insurance policies delivered, issued for delivery, or renewed in Michigan after December 31, 2025.

 

Proposed MCL 500.3406ff

 

BRIEF RATIONALE

 

According to testimony, three out of seven cancer patients who use orally administered chemotherapy skip doses or forego treatment because they cannot afford the out-of-pocket costs associated with the medication. Reasons to use orally administered chemotherapy over intravenously administered chemotherapy include its higher effectiveness against some types of blood cancer and the potential for less pain and bodily damage associated with treatment. Limiting the co-pay and co-insurance for orally administered chemotherapy could allow more cancer patients to benefit from its use.

 

PREVIOUS LEGISLATION

(This section does not provide a comprehensive account of previous legislative efforts on this subject matter.)

 

The bill is a reintroduction of House Bill 4354 from the 2021-2022 Legislative Session. House Bill 4354 passed the House but received no further action.

 

Legislative Analyst: Alex Krabill

 

FISCAL IMPACT

 

The bill would have no fiscal impact on State or local government.

 

Date Completed: 10-5-23 Fiscal Analyst: Elizabeth Raczkowski

This analysis was prepared by nonpartisan Senate staff for use by the Senate in its deliberations and does not constitute an official statement of legislative intent.